case_images: PMC6374873_01
case_images: Chest X-ray one and a half months after the initiation of everolimus treatment, showing no infiltrative shadows in both lung fields.
case_images: CRIU2019-2703871.001.jpg
case_images: PMC6374873_01_CRIU2019-2703871.001.jpg
case_images: fig1
case_images: At one and a half months after everolimus induction, the patient showed no remarkable respiratory symptom and no remarkable change was seen in the patient's chest X-ray (Figure 1).
case_images: (a) Chest X-ray two months after starting everolimus administration, showing diffuse infiltrative shadows in both lung fields. (b) Chest CT scan two months after starting everolimus administration, showing ground-glass attenuation with diffuse alveolar consolidation in both lung fields.
case_images: CRIU2019-2703871.002.jpg
case_images: PMC6374873_01_CRIU2019-2703871.002.jpg
case_images: fig2
case_images: Linear, reticular shadows were found in both lung fields during chest radiography (Figure 2(a)), and a chest CT revealed diffuse ground-glass opacities, thickening of the interlobular septa, and consolidation throughout both lung fields. Mild pericardial effusion was found, but there is no findings of suspecting cardiogenic pulmonary edema, which indicate acute respiratory distress syndrome (Figure 2(b)).